Xinbang Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 101 million yuan, a year-on-year decrease of 64.70%
Xinbang Pharmaceutical released its 2024 annual report, with operating revenue of 6.032 billion yuan, a year-on-year decrease of 6.63%; net profit attributable to the parent company was 101 million yuan, a year-on-year decrease of 64.70%. After deducting non-recurring gains and losses, the net profit was 165 million yuan, a year-on-year decrease of 38.29%. The basic earnings per share were 0.05 yuan, and it is proposed to distribute a cash dividend of 0.30 yuan for every 10 shares. The decline in net profit was mainly due to a decrease in revenue from the pharmaceutical distribution and medical services sectors, a decline in gross profit margin, and an increase in non-recurring gains and losses
According to the Zhitong Finance APP, Xinbang Pharmaceutical (002390.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 6.032 billion yuan, a year-on-year decrease of 6.63%. The net profit attributable to shareholders of the listed company was 101 million yuan, a year-on-year decrease of 64.70%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 165 million yuan, a year-on-year decrease of 38.29%. The basic earnings per share were 0.05 yuan. It is proposed to distribute a cash dividend of 0.30 yuan (including tax) for every 10 shares to all shareholders.
The main reason for the decline in net profit is the decrease in operating revenue from the pharmaceutical distribution sector and the medical services sector during the reporting period, a decline in overall gross profit margin, and an increase in non-recurring gains and losses
